Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia

Critical Care Medicine

Volumn 38, Issue 5, 2010, Pages 1261-1269

  Deane, Adam M ^a,b,c   Chapman, Marianne J ^a,b,c   Fraser, Robert J L ^c,d,e   Summers, Matthew J ^a   Zaknic, Antony V ^a   Storey, James P ^a,f   Jones, Karen L ^c,d   Rayner, Christopher K ^c,d   Horowitz, Michael ^c,d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e REPATRIATION GENERAL HOSPITAL   (Australia)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Blood glucose; Critical illness; Enteral nutrition; Gastric emptying; Glucagon like peptide 1; Hyperglycemia

Indexed keywords

3 METHYLGLUCOSE; CARBON 13; CARBON DIOXIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; OCTANOIC ACID; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INTENSIVE CARE UNIT; MALE; NUTRIENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING;

3-O-METHYLGLUCOSE; BLOOD GLUCOSE; BREATH TESTS; CRITICAL ILLNESS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; INTENSIVE CARE UNITS; RESPIRATION, ARTIFICIAL;

EID: 77951623571     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181d9d87a     Document Type: Article

References (45)

1. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367
2. Finfer S, Chittock DR, Su SY, et al: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297
3. Kreymann B, Williams G, Ghatei MA, et al: Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2:1300-1304 (Pubitemid 17156636)
4. Nauck MA, Heimesaat MM, Orskov C, et al: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91:301-307 (Pubitemid 23037285)
5. Little TJ, Pilichiewicz AN, Russo A, et al: Effects of intravenous glucagon-like pep-tide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91:1916-1923
6. Nauck MA, Heimesaat MM, Behle K, et al: Effects of glucagon-like peptide 1 on coun-terregulatory hormone responses, cognitive functions, and insulin secretion during hy-perinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin En-docrinol Metab 2002; 87:1239-1246 (Pubitemid 36121094)
7. Zander M, Madsbad S, Madsen JL, et al: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359:824-830 (Pubitemid 34233752)
8. Meier JJ, Nauck MA, Kranz D, et al: Secretion, degradation, and elimination of gluca-gon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53:654-662 (Pubitemid 38270634)
9. Kovalaske MA, Gandhi GY: Incretins in the ICU: Is insulin on its way out? Crit Care 2009; 13:161
10. Deane AM, Chapman MJ, Fraser RJ, et al: The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: A randomised double-blind placebo controlled cross over study. Crit Care 2009; 13:R67
11. Deane AM, Fraser RJ, Chapman MJ: Proki-netic drugs for feed intolerance in critical illness: Current and potential therapies. Crit Care Resusc 2009; 11:132-143
12. Martindale RG, McClave SA, Vanek VW, et al: Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. Crit Care Med 2009; 37:1757-1761
13. Delgado-Aros S, Vella A, Camilleri M, et al: Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastro-enterol Motil 2003; 15:435-443 (Pubitemid 36876259)
14. Linnebjerg H, Park S, Kothare PA, et al: Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151:123-129
15. Nauck MA, Walberg J, Vethacke A, et al: Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glu-cagon-like peptide 1. Regul Pept 2004; 118: 89-97 (Pubitemid 38167370)
16. Meier JJ, Weyhe D, Michaely M, et al: Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32:848-851 (Pubitemid 38340086)
17. Chapman MJ, Fraser RJ, Matthews G, et al: Glucose absorption and gastric emptying in critical illness. Crit Care 2009; 13:R140
18. Deane A, Nguyen N, Stevens J, et al: Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95:215-221
19. Ritz MA, Fraser R, Edwards N, et al: Delayed gastric emptying in ventilated critically ill patients: Measurement by 13 C-octanoic acid breath test. Crit Care Med 2001; 29: 1744-1749 (Pubitemid 32848375)
20. Ritz MA, Chapman MJ, Fraser RJ, et al: Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill. Intensive Care Med 2005; 31: 949-954
21. Uhing MR, Kimura RE: The effect of surgical bowel manipulation and anesthesia on intestinal glucose absorption in rats. J Clin Invest 1995; 95:2790-2798
22. Heyland DK, Tougas G, King D, et al: Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996; 22:1339-1344 (Pubitemid 27007768)
23. Nguyen NQ, Fraser RJ, Bryant LK, et al: The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and pep-tide YY concentrations in critically ill patients. Crit Car e Med 2008; 36:1469-1474
24. Cumming G, Finch S: Inference by eye: Confidence intervals and how to read pictures of data. Am Psychol 2005; 60:170-180 (Pubitemid 40345895)
25. Meier JJ, Gethmann A, Nauck MA, et al: The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol 2006; 290:E1118-E1123 (Pubitemid 43847894)
26. Schirra J, Nicolaus M, Roggel R, et al: Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55:243-251 (Pubitemid 43117285)
27. Bland JM, Altman DG: Calculating correlation coefficients with repeated observations: Part 1-Correlation within subjects. BMJ 1995; 310:446
28. Horowitz M, Edelbroek MA, Wishart JM, et al: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36:857-862 (Pubitemid 23248159)
29. Jones KL, Horowitz M, Wishart MJ, et al: Relationships between gastric emptying, in-tragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med 1995; 36:2220-2228
30. Young RL, Sutherland K, Pezos N, et al: Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes. Gut 2009; 58: 337-346
31. Tolessa T, Gutniak M, Holst JJ, et al: Gluca-gon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284-2290 (Pubitemid 28487260)
32. Hellstrom PM, Naslund E, Edholm T, et al: GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20:649-659 (Pubitemid 351678618)
33. Qin X, Shen H, Liu M, et al: GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol 2005; 288:G943-G949 (Pubitemid 40563135)
34. Meier JJ, Kemmeries G, Holst JJ, et al: Eryth-romycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54:2212-2218 (Pubitemid 40911286)
35. Sokos GG, Bolukoglu H, German J, et al: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100: 824-829 (Pubitemid 47268274)
36. Mussig K, Oncu A, Lindauer P, et al: Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008; 102: 646-647
37. Egi M, Bellomo R, Stachowski E, et al: Blood glucose concentration and outcome of critical illness: The impact of diabetes. Crit Care Med 2008; 36:2249-2255
38. Meier JJ, Gallwitz B, Salmen S, et al: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like pep-tide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:2719-2725 (Pubitemid 36733545)
39. Drucker DJ, Buse JB, Taylor K, et al: Ex-enatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 2008; 372:1240-1250
40. Nguyen NQ, Chapman MJ, Fraser RJ, et al: The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med 2008; 34: 454-460
41. Zaknic A, Summers M, Deane A, et al: Intra-subject variability of gastric emptying in the critically ill using the [13C]octanoic acid breath test. Anaesth Intensive Care 2009; 37:1036 [abstract]
42. Meier JJ, Goetze O, Anstipp J, et al: Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol 2004; 286:E621-E625 (Pubitemid 38374960)
43. Schvarcz E, Palmer M, Aman J, et al: Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastro-enterology 1997; 113:60-66 (Pubitemid 27281758)
44. Vilsboll T, Krarup T, Sonne J, et al: Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Clin Endocrinol Metab 2003; 88:2706-2713 (Pubitemid 36724446)
45. Holst JJ: Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49:253-260